Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002225 · ClinicalTrials.gov registry record · Phase 2
A Study of Efavirenz in Combination With Stavudine and Didanosine
A Phase 2 study of HIV Infections, sponsored by Dupont Merck.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 5
- Study locations
NCT00002225: Completed Phase 2 study of HIV Infections, sponsored by Dupont Merck.
NCT00002225 is a Phase 2 study of HIV Infections that has completed, run by Dupont Merck. The registered enrollment target is 60 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002225, a Phase 2 study of HIV Infections, has completed, sponsored by Dupont Merck.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to see if it is safe and effective to give efavirenz plus stavudine plus didanosine to HIV-infected patients who have never received anti-HIV treatment.
Conditions Studied
Interventions
- DRUG Efavirenz
- DRUG Stavudine
- DRUG Didanosine
Study Locations (5)
New York
- North Shore AIDS Hosp / Division of Infectious Disease - Manhassett
- Univ of Rochester Med Ctr - Rochester
District of Columbia
- The Whitman Walker Clinic - Washington D.C.
Illinois
- AIDS Research Alliance - Chicago - Chicago
North Carolina
- Carolinas Research Associates - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002225
The ClinicalTrials.gov registry entry for NCT00002225 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The listed sponsor is Dupont Merck, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Efavirenz is the first listed.
NCT00002225 reports 5 study locations spanning 4 distinct geographic areas - top geographies include New York, District of Columbia, Illinois.
Frequently Asked Questions
What is clinical trial NCT00002225 about?
NCT00002225 is a clinical study titled "A Study of Efavirenz in Combination With Stavudine and Didanosine". The purpose of this study is to see if it is safe and effective to give efavirenz plus stavudine plus didanosine to HIV-infected patients who have never received anti-HIV treatment.
What is the current status of trial NCT00002225?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants.
What conditions does trial NCT00002225 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002225?
The interventions under investigation include: Efavirenz (DRUG), Stavudine (DRUG), Didanosine (DRUG).
Who is sponsoring clinical trial NCT00002225?
This trial is sponsored by Dupont Merck, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002225 being conducted?
This trial has 5 study locations across District of Columbia, Illinois, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.